Biography:

Dr Syed Bilal Tanvir has completed his MD in Medicine and a higher Masters in Clinical Microbiology and Infection Control from the Prestigious Queen Mary, University of London at the age of 26 years. He is currently working as a faculty member and course director of Infection and Host Defense and Disease Transmission and Infection control at Dar Al Uloom University, Riyadh, Saudi Arabia .He is also working as an infection control specialist at Dar Al Uloom University Hospital. He has published more than 12 papers in reputed journals and have presented his research  internationally in Bahrain, Karachi, and Jeddah previously.
 

Abstract:

Background: Acute bacterial skin and skin structure (ABSSSI) infections can cause a significant amount of morbidity and mortality in hospitalized patients and outpatients as well. Emerging resistance of Gram-positive pathogens to different drugs has narrowed down our options for treating skin infections. Newer antimicrobials such as delafloxacin might prove to be a useful alternative to treat skin infections caused by resistant gram-positive pathogens.

The objective of this review is to assess all the available evidence on delafloxacin in literature and compare its efficacy with drugs routinely used to treat skin infections.

Methodology: An extensive literature search was conducted using different databases. By using Pubmed, Embase and Cochrane central register of controlled trials 86 abstracts were screened for eligibility. A total of 6 studies were finally included in the narrative review and meta-analysis. The primary outcome in this review was to assess the microbiological cure at the end of the follow up period. Secondary outcome was clinical response and absence of the signs and symptoms at the end of the follow up period.

Results: A total of 86 abstracts were screened for review, out of the 86 abstracts, 25 studies were  further screened for eligibility, only 6 studies were finally included in the narrative review and meta- analysis. By using RevMan Software Risk Ratio (RR) random effects model was used with 95% Confidence interval. The pooled efficacy of  Delafloxacin was at 80%  95 CI 1.01 (0.97, 1.06) P = 0.51. No statistically significant difference was found between Intravenous (IV delafloxacin) and Comparator drugs.

Conclusion: Despite having a pooled cure rate of 80%, the efficacy of Delafloxacin was found to be non-inferior to Tigegcycline and Linezolid. Pooled cure rate and efficacy of Delafloxacin was also found to be superior to Vancomycin. Therefore, it can be ascertained that Delafloxacin might prove as a useful alternative for treating resistant Gram-positive infections. However, more high quality randomized controlled trials, need to be conducted in future in order to develop clinical guidelines.

Biography:

Uma Nahar Saikia has completed her MD, Pathology from NIMS, India and is currently working as a professor at  the Department of Histopathology,  PGIMER,India. She is a member of International Medical sciences Academy (FIMSA), International Society for Dermatopathology (ISDP),Member of National Academy of Medical Sciences(NAMS),Indian Society of Heart Research (ISHR), Dermatopathology Society of India (DSI), Indian association of Pathologists and Microbiologists (IAPM). She has published more than 200 international and 49 national papers in reputed journals

Abstract:

Title: Role of HPV 6/11 in Giant condylomas in Indian patients.

Uma Nahar Saikia¹,  Suvradeep Mitra¹, Tirupti Rangta², Mini P Singh², and Dipankar De³.

Departments of Histopathology, Virology and Dermatology and Venereology and Leprology, Postgraduate Institute of medical Education and research, Chandigarh, India

Introduction:  Genital warts are quite common in sexually active population with Human papilloma virus (HPV) as the causative agent. In western literature HPV6/11 as an etiological factor varies from 80 to 90% , however there is a paucity of literature in India about the type of virus causing condylomata .

Material and Methods: A total of 22 histologically confirmed cases of condylomata acuminata were included in the study over a period of 2 years(2014-2016). The majority (19/22; 86.3%) of the biopsy samples were from genital & perianal areas. Formalin Fixed Para-film (FFPE) embedded sections were used  for HPV 6 &11 using 2-3, 20-30 micron sections. The targets used were L1 & E6 region of HPV 6 and 11 respectively.

Result: Clinically, 18 patients had  giant condylomas and 4 had multiple lesions. There was male preponderance (95.4%) with mean age of 46.3 (18-84 years). Histologically marked acanthosis with papillomatosis was noted. There was moderately dense lymphoplasmacytic infiltrate   in the upper dermis with vascular proliferation. Koilocytic change was seen in 10 (71.4%) cases which correlated with PCR positivity in 10 cases.. On PCR 14 cases (63.6%) were positive for HPV 6 or 11; HPV 6 alone was present in eight cases (36.3%) and HPV 11 in six cases (27.2%). No dual infection was present. The HPV 6/11 positivity correlated with higher degree of inflammation. Three cases with clinical diagnosis of syphilis, Ewing’s sarcoma and carcinoma breast repectively were negative for HPV 6 & HPV 11.

Conclusion: The PCR results confirmed the presence of HPV6/11 in 63.6% of condylomata acuminata cases.  Five morphologically confirmed cases were negative for HPV 6 & 11, possibly due to late stage of infection with no significant  inflammation or koilocytic change.  Hence HPV vaccination to be used in prevention of giant condylomas caused by HPV 6 or 11.

Biography:

Abstract: